Adhere to Firmer Study Archival Requirements with Egnyte's eTMF
Fines and penalties for regulatory noncompliance within biopharma have been well documented. Since 2000, violations for noncompliance have cost biopharma $50B—and the costs of addressing root causes of noncompliance have grown as well, climbing by more than 40% since 2011 according to some estimates. The costs of remediating a deficiency can vary considerably, from as little as $250K to $5M for a Form 483 cited deficiency.